Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

11/20/2026
BreakingDealsPharmaRetina
J&J to Acquire Ollin Biosciences for $2.2 Billion Up Front, Plus Milestone Payments
J&J to Acquire Ollin Biosciences for $2.2 Billion Up Front, Plus Milestone Payments
Johnson & Johnson announced Nov. 16 that it would acquire Ollin Biosciences and its retinal treatment candidate OLN324 for $2.2 billion up front, with the potential for up to $1.125 billionin addit...
11/20/2026
BreakingCataractFLACSGlaucomaLaserOcular CancerRevenueSurgical
Q3-2026 Ophthalmic Revenue Roundup for Immunocore, Lensar, and Iridex
Q3-2026 Ophthalmic Revenue Roundup for Immunocore, Lensar, and Iridex
UK-headquartered Immunocore reported Nov. 6 that its Q3-2026 net revenue from Kimmtrak (tebentafusp) was $102.2 million, a 1.4 percent decline from $103.7 million in Q3-2025. Regionally, Kimmtrak n...
11/20/2026
BreakingDeviceEuropeRegulationRetina
MacuMira Gains CE Marking for Microcurrent Treatment for Dry AMD
MacuMira Gains CE Marking for Microcurrent Treatment for Dry AMD
MacuMira Medical Devices, of Calgary, Alberta, reported Nov. 16 that its retinal microcurrent stimulation device had gained CE marking for the treatment of dry age-related macular degeneration (AMD...
11/17/2026
EuropeMeetingNewsletterRetina
Euretina Congress Embraces a Global Role as it Becomes Biggest Retina Meeting
Euretina Congress Embraces a Global Role as it Becomes Biggest Retina Meeting
Euretina openly embraced its identity as a global organization this year. Euretina has emerged since 2023 as the premier and largest meeting for retina doctors in the world. A record 11,144 people ...
11/20/2026
BiosimilarsBreakingDealsRetina
Sandoz Launches Enzeevu in the US, Announces Private Label Agreement
Sandoz Launches Enzeevu in the US, Announces Private Label Agreement
Swiss drugmaker Sandoz announced Nov. 16 the US launch of its Eylea biosimilar, Enzeevu (aflibercept-abzv) 2 mg, available in a pre-filled syringe. Enzeevu was approved in the US in August 2024. It...
11/20/2026
BreakingOptometry
High Point University Prepares to Open North Carolina’s First School of Optometry
High Point University Prepares to Open North Carolina’s First School of Optometry
North Carolina’s High Point University announced Nov. 12 that it had gained preliminary approval from the Accreditation Council on Optometric Education (ACOE), clearing the way for High Point to op...
11/20/2026
BreakingDealsGene TherapyRetina
Ocugen Licenses RP Gene Therapy Candidate to Celairis for Australia, New Zealand, ASEAN Countries
Ocugen Licenses RP Gene Therapy Candidate to Celairis for Australia, New Zealand, ASEAN Countries
Ocugen announced Nov. 10 that it had granted Australia’s Celairis Therapeutics exclusive rights to commercialize OCU400, Ocugen’s subretinal modifier gene therapy candidate targeting retinitis pigm...
11/20/2026
BreakingClinical TrialGene TherapyRegulationRetina
SparingVision Gets Green Light to Expand RP Gene Therapy Trial to US
SparingVision Gets Green Light to Expand RP Gene Therapy Trial to US
France’s SparingVision announced on LinkedIn on Nov. 12 that the FDA had signed off on its investigational new drug (IND) application, allowing the company to expand its clinical trial of SPVN20, a...
11/17/2026
AAOMeetingNewsletter
Hurricane Threat, Dip in International Attendance Impact AAO Meeting
Hurricane Threat, Dip in International Attendance Impact AAO Meeting
More than 13,200 people attended the 2026 meeting of the American Academy of Ophthalmology, held Oct. 10-12 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Another 2,208 regist...
11/17/2026
AAOClinical TrialMeetingMyopiaNewsletter
CCOI Breakfast Highlights Work to Standardize Trials
CCOI Breakfast Highlights Work  to Standardize Trials
Regulatory uncertainty was a main theme at the latest meeting of the Collaborative Community on Ophthalmic Innovation (CCOI). The multi-stakeholder nonprofit, designed to break down traditional sil...
11/17/2026
CataractIOLNewsletterPremiumSurgical
PC-IOLs Drive Next Wave of Global Growth in Premium Cataract Surgery
PC-IOLs Drive Next Wave of Global Growth in Premium Cataract Surgery
PC-IOLs have become the principal growth engine of the global premium cataract surgery (PCS) market, despite making only modest gains in penetration since their introduction in the late 1990s and e...
11/17/2026
CataractNewsletterPremiumSurgical
Do More Cataract Surgeons Mean Higher Premium IOL Rates?
Do More Cataract Surgeons Mean Higher Premium IOL Rates?
Metro areas with more cataract surgeons generally have more premium practices, but the pattern has notable exceptions, according to Market Scope’s “2026 US Cataract Atlas.” Boston, Massachusetts, a...

Past News Stories

11/17/2026
ChinaMyopiaNewsletterRefractiveRegulationSurgical
Chinese Regulators Approve PT Lunana Phakic IOL from Zeiss for Myopia
Chinese Regulators Approve PT Lunana Phakic IOL from Zeiss for Myopia
German company Carl Zeiss Meditec announced on Nov. 9 that China’s National Medical Products Administration (NMPA) had approved the company’s PT Lunana phakic intraocular lens (IOL). The lens was s...
11/17/2026
AcquisitionsCataractDealsIndiaNewsletter
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
India’s Appasamy Associates, a portfolio company of Warburg Pincus, reported Oct. 22 that it had acquired German company Ruck, manufacturer of ophthalmic surgical products for both the front and ba...
11/17/2026
CataractDiagnosticNewsletterRegulation
Select US FDA Approvals and Clearances in October 2026
Select US FDA Approvals and Clearances in October 2026
The US FDA’s ophthalmic device division granted clearance to two devices using the 510(k) pathway in October 2026, according to the agency’s database. Carl Zeiss Meditec received clearance for its ...
11/17/2026
GlaucomaNewsletterRegulationRetina
PDUFA Dates for Ophthalmic Drug Candidates, November 2026
PDUFA Dates for Ophthalmic Drug Candidates, November 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
11/17/2026
MyopiaNewsletterRegulation
FDA Panel Meeting on Sydnexis’ Drop for Myopia is Marked by Parsing of Data, Pleas from Providers
FDA Panel Meeting on Sydnexis’ Drop  for Myopia is Marked by Parsing of Data,  Pleas from Providers
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’ ...
11/17/2026
Clinical TrialNewsletterRetina
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...
11/17/2026
CornealDealsFundingGlaucomaNewsletterRetina
Surrozen Leads Latest Fundraising with $95.1 Million Private Placement
Surrozen Leads Latest Fundraising with $95.1 Million Private Placement
Surrozen led recent ophthalmic fundraising efforts with $95.1 million from a second tranche of a private placement to advance its retinal pipeline. Financing announced in the past four weeks totale...
11/17/2026
AIDiagnosticEuropeIndustryMeetingNewsletterRetinaRoboticsSurgical
Innovation Meetings Tackle Different Facets of Retinal Care
Innovation Meetings Tackle Different Facets of Retinal Care
The two big innovation meetings at the 2026 Euretina congress in Vienna, Austria, had overlapping time slots, but they targeted different audiences. The half-day Euretina Innovation Spotlight (EIS)...
11/17/2026
Clinical TrialDeviceDiagnosticEuropeGene TherapyMeetingNewsletterOCTPharmaRetina
Euretina Congress Turns Spotlight on Possible Paradigm Shifts
Euretina Congress Turns Spotlight on Possible Paradigm Shifts
Euretina’s program committee captured the intellectual ferment in retina with several presentations challenging established paradigms. Sandrine Zweifel, MD, PhD (Switzerland), got the ball rolling ...
11/17/2026
BreakingCataractEuropeGlaucomaIndiaIndustryMeetingNewsletterRefractiveRetina
2026-2027 Ophthalmic Meetings Calendar
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
11/17/2026
CataractDeviceDiagnosticEuropeFundusLow VisionMeetingNewsletterOCTOptometryPharmaRetinaSurgical
Hot Topics at Euretina Congress Include Wet AMD Dosing Intervals, New Products
Hot Topics at Euretina Congress Include Wet AMD Dosing Intervals, New Products
Celine Lee, MD (Denmark), reported at the 2026 Euretina congress that 37 of 311 eyes (11.9 percent) in the Danish RIDE-AMD Initiative were able to discontinue aflibercept treatment. “In Denmark, we...
11/17/2026
AAOAIClinical TrialEyeceleratorIOLMeetingNewsletterRegulationRetina
Eyecelerator Weighs Current Problems, Potential Solutions in Innovation
Eyecelerator Weighs Current Problems, Potential Solutions in Innovation
Eyecelerator participants discussed some of the challenges holding back innovation to a room filled with attendees, despite the threat of extreme weather from Hurricane Isaias. The forum was held O...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.